



Universiteit
Leiden
The Netherlands

Healthy elderly in clinical trials: how to define preclinical Alzheimer's Disease for clinical trial participation

Prins, S.

Citation

Prins, S. (2023, April 5). *Healthy elderly in clinical trials: how to define preclinical Alzheimer's Disease for clinical trial participation*.

Retrieved from <https://hdl.handle.net/1887/3590274>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3590274>

Note: To cite this publication please use the final published version (if applicable).

CHAPTER VI

**Inflammatory plasma biomarkers in subjects with preclinical
Alzheimer's disease**

Samantha Prins,^{1,2} Marieke L. de Kam,¹ Charlotte E. Teunissen,² Geert Jan Groeneveld^{1,2}

ALZHEIMER'S RESEARCH & THERAPY (2022) 14:106

DOI:10.1186/S13195-022-01051-2, EPUB 3 AUGUST 2022

1. Centre for Human drug Research, Leiden, NL | 2. Leiden University Medical Center,
Leiden, NL | 3. Neurochemistry Laboratory, Department of Clinical Chemistry,
Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, NL

ABSTRACT

BACKGROUND This study investigated plasma biomarkers for neuroinflammation associated with Alzheimer's Disease (AD) in subjects with preclinical AD compared to healthy elderly. How these biomarkers behave in patients with AD, compared to healthy elderly is well known, but determining these in subjects with preclinical AD is not and will add information related to the onset of AD. When found to be different in preclinical AD, these inflammatory biomarkers may be used to select preclinical AD subjects who are most likely to develop AD, to participate in clinical trials with new disease modifying drugs.

METHODS Healthy elderly ($n=50$; age 71.9; MMSE >24) and subjects with preclinical AD ($n=50$; age 73.4; MMSE >24) defined by CSF $A\beta_{1-42}$ levels <1000 pg/mL were included. Four neuroinflammatory biomarkers were determined in plasma, GFAP, YKL-40, MCP-1 and Eotaxin-1. Differences in biomarker outcomes were compared using ANCOVA. Subject characteristics age, gender and ApoE $\epsilon 4$ status were reported per group and were covariates in the ANCOVA. Least square means were calculated for all 4 inflammatory biomarkers using both the $A\beta+$ / $A\beta-$ cut off and PTAU/ $A\beta_{1-42}$ ratio.

RESULTS The mean (Standard Deviation, SD) age of the subjects ($n=100$) was 72.6 (4.6) years old with 62 male and 38 female subjects. Mean (SD) overall MMSE score was 28.7 (0.49) and 32 subjects were ApoE $\epsilon 4$ carriers. The number of subjects in the different ApoE $\epsilon 4$ status categories differed significantly between the $A\beta+$ and $A\beta-$ group. Plasma GFAP concentration was significantly higher in the $A\beta+$ group compared to the $A\beta-$ group with significant covariates age and sex, variables that also correlated significantly with GFAP.

CONCLUSION GFAP was significantly higher in subjects with preclinical AD compared to healthy elderly which agrees with previous studies. When defining preclinical AD based on the PTAU181/ $A\beta_{1-42}$ ratio, YKL-40 was also significantly different between groups. This could indicate that GFAP and YKL-40 are more sensitive markers of the inflammatory process in response to the $A\beta$ misfolding and aggregation that is ongoing as indicated by the lowered $A\beta_{1-42}$ levels in the CSF. Characterizing subjects with preclinical AD using neuroinflammatory biomarkers is important for subject selection in new disease modifying clinical trials.

BACKGROUND

Biomarkers for Alzheimer's Disease (AD) are primarily validated based on observed differences between cognitively healthy elderly and AD patients.¹⁻⁵

Investigating biomarkers in subjects with preclinical AD (AD biomarker positive but cognitively normal) is important as clinical trials of new drugs shift to disease prevention in the still cognitively normal elderly.^{6,7} Biomarker changes may present itself as early as 20 years prior to disease onset and therefore early intervention is important.⁸ Selecting subjects with preclinical AD for clinical trials may aid in demonstrating modification of disease progression due to treatment with drugs targeting core pathophysiological processes and treatment of patients with preclinical AD may ultimately prevent conversion to AD. Characterization of individuals with preclinical AD by identifying biomarkers indicative of the earliest pathophysiological processes involved in AD is therefore of the utmost importance. Preferably minimally invasive methods are used to identify AD pathology, especially in otherwise healthy subjects.

The accumulation of amyloid plaques and intracellular neurofibrillary tangles consisting of misfolded phosphorylated tau (PTAU) protein during the development of AD eventually leads to synaptic dysfunction after which axonal damage occurs and cognitive changes can be observed. While this protein related process is ongoing, the immune system is also responsive.⁹

Misfolded and aggregated proteins can bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterized by release of inflammatory mediators, which contribute to disease progression and severity.¹⁰ Differences in immune CSF biomarkers, such as YKL-40, MCP-1 and eotaxin-1 have been well established between healthy elderly and AD patients.¹¹⁻¹⁵ An observable neuroinflammatory response of the immune system to protein aggregation could mean that the process of neurodegeneration leading to AD has already started.⁹ Measurement of these innate neuroimmune response related biomarkers in the preclinical AD stages may help to predict which cognitively healthy elderly are more likely to develop AD.

YKL-40 (also known as chitinase-3-like protein-1 [CHI3L1]) is a glycoprotein, which is mainly expressed in astrocytes. AD patients have significantly higher YKL-40 levels in the CSF compared with healthy controls however it is not a specific biomarker for AD, because it merely reflects the inflammatory progress. YKL-40 is suitable as a marker for clinical drug trials to give information about neurodegeneration and glial activation independently of tau and A β .¹² Plasma YKL-40 levels have been investigated in patients with AD and in healthy elderly controls,¹⁵ but not yet in subjects with preclinical AD.

Glial fibrillary acidic protein (GFAP) is a marker for astrogliosis and has been reported to be increased postmortem in brains of patients with AD and in CSF of patients with AD.^{16,17} Verberk et al., (2021) found GFAP to be associated with increased risk of dementia and a steeper rate of cognitive decline and they conclude that GFAP has the potential to be a prognostic blood-based biomarker for AD in their cohort of cognitively normal older people.¹⁸ Another recent study showed elevated plasma GFAP levels in subjects with preclinical AD which could mean that astrocytic damage or activation starts in the preclinical phase of AD.¹⁹

Chemokines are a family of chemoattractant, which play a vital role in cell migration from blood into tissue and vice versa, and in the induction of cell movement in response to a chemical (chemokine) gradient by a process known as chemotaxis.²⁰ In addition, chemokines have recently been shown to have a function in the nervous system as neuromodulators. Two chemokines (monocyte chemoattractant protein-1 [MCP-1] and eotaxin-1) have previously been reported to be correlated with greater memory impairment in MCI and AD.¹¹ In a recent study these chemokines were demonstrated to be able to discriminate between healthy subjects and subjects with MCI and AD.¹³

In the current study we aimed to investigate plasma biomarkers related to neuroinflammation associated with AD in a cohort of subjects with preclinical AD and to compare these to healthy elderly. Using a preclinical subject population will add valuable information to the body of literature on the onset of AD.

METHODS

This was an exploratory sub-study of a previously performed study registered in the international trial register with ID number: ISRCTN79036545. All study participants provided written consent for exploratory analyses of material obtained during study execution.

The main study was approved by the ethics committee of the Leiden University Medical Center (LUMC), the Netherlands. The study was conducted according to the Dutch act on Medical Research Involving Human Subjects (WMO) and in compliance with Good Clinical Practice (ICH-GCP) and the Declaration of Helsinki.

PARTICIPANTS Samples of 100 healthy male and female participants of 65 years of age and older were selected from the main study in healthy elderly.²¹ All subjects were healthy volunteers without cognitive complaints who registered for participation voluntarily. Of these 100 subjects, 50 subjects were selected with a CSF

$A\beta_{1-42}$ profile consistent with Alzheimer's disease and were classified as subjects with probable brain amyloidosis, referred to as preclinical AD. A healthy control group of 50 subjects was selected based on subjects having high levels of CSF $A\beta_{1-42}$. $A\beta_{1-42}$ was measured in CSF using the fully automated Elecsys platform.²² at the Neurochemistry Lab Amsterdam UMC, using in-house confirmed cut-offs.²³ Lowered $A\beta$ levels classified as amyloid abnormal and consistent with the presence of Alzheimer pathology were dichotomized by creating a group of ' $A\beta$ positive subjects' ($A\beta+ = < 1000$ PG/mL) and ' $A\beta$ negative subjects' ($A\beta- = > 1000$ PG/mL). All the subjects visited Centre for Human Drug Research (CHDR) between October 2017 and November 2018. Main exclusion criteria were a diagnosis of a cognitive disorder (including but not limited to MCI, AD, Lewy Body dementia [LBD], Frontotemporal dementia [FTD]), history of psychiatric disease in the past 3 years, Mini Mental State Examination (MMSE) ≤ 24 , Geriatric Depression Scale (GDS) ≥ 6 , presence of drug or alcohol abuse (< 2 standard drinks per day for female and < 3 standard drinks per day for male), use of any medication that was expected to influence central nervous system function or is contraindicated of the performance of a lumbar puncture.

All subjects visited the clinical research unit once and underwent blood sampling at predefined time points (0, 2 and 4 hour[s]). A single lumbar puncture was performed for the collection of CSF (at 4 hours, either in the morning or afternoon). Furthermore, an automated CNS test battery was performed to collect data related to different domains of CNS functioning. The Clinical Dementia Rating scale (CDR) was assessed during the study day.

In the context of a post hoc analysis, subjects were also dichotomized based on the PTAU/ $A\beta_{1-42}$ ratio. Previous studies have shown that the use of ratio scores may be superior to the use of a single biomarker.^{24,25} PTAU information was known from the main study and determined by measuring PTAU in CSF using the fully automated Elecsys platform.²² at the Neurochemistry Lab Amsterdam UMC, using the PTAU/ $A\beta_{1-42}$ ratio > 0.02 cut-off for preclinical AD definition. Subjects with a score < 0.02 were classified as healthy subjects.

BLOOD SAMPLING Approximately 10 mL blood was collected via an i.v. catheter placed in an antecubital vein in the arm in appropriate K2EDTA tubes (BD, USA) at the predefined time points mentioned above. Following blood centrifugation within one hour at 2000g for 10 min at 4°C, the plasma aliquots were divided into 0.5 mL aliquots in Sarstedt polypropylene tubes and stored at -80°C. All blood samples for analyses of YKL-40, GFAP, MCP-1 and Eotaxin-1 are collected in a non-fasted state within one hour of collection of the CSF sample

LUMBAR PUNCTURE Lumbar punctures were performed by a trained, physician with a 25G atraumatic lumbar puncture needle (Braun, 25G). The needle was placed at the L3-L4 or L4-L5 interspace with the subject in supine or sitting position. 4 ml CSF was collected in a 15 mL polypropylene tube (Corning, USA). CSF was centrifuged within one hour, at 2000g for 10 minutes at 4°C and stored at -80°C.²⁶

APOLIPOPROTEIN E GENOTYPING Apolipoprotein E (ApoE) genotyping was performed after isolating DNA from EDTA blood by the laboratory of human genetics (department of human genetics and endocrinology, Leiden University Medical Center LUMC). DNA was isolated using QIAamp DNA Blood MINI kit after which a polymerase chain reaction (PCR) technique was applied on the clean DNA. A sequential analysis (according to the Sanger method) than determined the ApoE genotype. One or 2 ApoE ϵ 4 alleles classified subjects as ApoE ϵ 4 carriers, when no ApoE ϵ 4 alleles were present a subject was classified as noncarrier.

MEASUREMENT OF YKL-40, GFAP, MCP-1 AND EOTAXIN-1 YKL-40 (Chitinase 3-like 1 [CHI3LI]) was measured in the plasma samples using the CHI3LI Human ELISA Kit (Thermo Fisher) according to the manufacturer's instructions. YKL-40 was measured previously in a larger sample and not for the sole purpose of this study.²¹ Results of the 100 subjects selected for this study, have been used in the analyses. Plasma GFAP concentrations were measured at Amsterdam University Medical Centers (Amsterdam UMC) using the Simoa GFAP Discovery kit on the Single molecule array (Simoa) platform (Quanterix, Billerica, USA). MCP-1 and Eotaxin-1 were also measured at the Amsterdam UMC using Meso scale discovery (MSD, Rockville, MD, USA) assays according to the kit instructions.

STATISTICAL METHODOLOGY Visual checks on the ranges of biomarker and clinical characteristic test scores for each group based on CSF amyloid beta status, were done using scatter plots, as well as Tukey boxplots. Independent T-Test, Pearson Chi-Square test and Mann-Whitney tests were applied as appropriate.

To establish differences between subject groups in biomarkers, data is analysed using an ANCOVA, where age, sex and E4 status are added to the model as covariate. After including all covariates, the analysis was repeated with only the significant covariates added to the model. Variables were Log transformed where applicable. Least square means were calculated for all 4 inflammatory biomarkers using both the $A\beta^{+}/A\beta^{-}$ cut off and PTAU/ $A\beta_{1-42}$ ratio. All analyses were carried out using SAS for Windows V9.4 (SAS Institute, Inc., Cary, NC, USA). A p-value of <0.05 was considered significant.

RESULTS

DEMOGRAPHIC AND CLINICAL CHARACTERISTICS The mean age of the total group of study participants (n=100) was 72.6 (4.6) years old with 62 male and 38 female subjects. Mean overall MMSE score was 28.7 (0.49) and 32 subjects were ApoE ϵ 4 carriers. All subjects had a CDR score of 0.

COMPARISON OF PLASMA YKL-40, GFAP, MCP-1 AND EOTAXIN-1 BETWEEN A β + AND A β - SUBJECTS Table 1 presents the cross-sectional demographics and clinical characteristics of the studied population based on A β + / A β - groups. The ApoE ϵ 4 status were significantly different between A β + and A β - subjects. All other clinical characteristics do not differ significantly between the A β + and A β - group. Plasma GFAP concentration was significantly higher in the A β + group compared to the A β - group before and after adjusting for covariates age and sex, variables that also correlated significantly with GFAP, see figure 2. YKL-40, MCP-1 and Eotaxin-1 were not significantly different between the A β + and A β - group. None of the biomarkers correlated with the MMSE score.

Table 1 Cross-sectional demographics and clinical characteristics of the studied population based on A β + / A β - groups.

	A β + (n=50)	A β - (n=50)	p
A β level (mean, SD)	706.0 (174.36)	>1700	
Sex (male/female)	33/17	29/21	0.41
BMI (mean, SD)	26.07 (3.95)	25.17 (3.44)	0.225
Age (years, mean, SD)	73.40 (4.72)	71.88 (4.45)	0.101
ApoE ϵ 4 carrier (n, %)	25 (50%)	7 (14.6%)	0.003
MMSE (mean, SD)	28.60 (1.41)	28.82 (1.37)	0.431
CDR (mean, SD)	0 (0)	0 (0)	
GFAP PG/mL (mean, SD)	N=50 195.1 \pm 87.13	N=50 134.0 \pm 50.71	<0.001
YKL-40 PG/mL (mean, SD)	N=49 54662.3 \pm 39697.31	N=49 82947.1 \pm 83418.38	0.397
MCP-1 PG/mL (mean, SD)	N=50 91.74 \pm 16.72	N=50 97.98 \pm 34.01	0.358
Eotaxin-1 PG/mL (mean, SD)	N=50 195.0 \pm 57.87	N=50 204.0 \pm 94.80	0.783

P values in bold font were considered significant ($p < 0.05$). Independent T-Test and Pearson Chi-Square test were applied as appropriate.

COMPARISON OF PLASMA YKL-40, GFAP, MCP-1 AND EOTAXIN-1 BETWEEN SUBJECTS DIVIDED BASED ON PTAU/A β ₄₂ RATIO Table 2 presents the cross-sectional demographics and clinical characteristics of the studied population based on the PTAU/A β ₁₋₄₂ ratio score. The ApoE ϵ ₄ status were significantly different between two groups divided by PTAU/A β ₁₋₄₂ ratio score. All other clinical characteristics do not differ significantly groups. Plasma GFAP and plasma YKL-40 concentration were significantly higher in the preclinical AD group based on the PTAU/A β ₁₋₄₂ ratio before and after adjusting for covariates age, sex and ApoE ϵ ₄ status as these variables also correlated with GFAP, see figure 3. YKL-40 was significantly different between ApoE ϵ ₄ carriers versus non-carriers. Eotaxin-1 was significantly different between sexes. MCP-1 did not show any difference.

Table 2 Cross-sectional demographics and clinical characteristics of the studied population based on the PTAU/A β ₁₋₄₂ ratio score.

	PTAU/A β + (n=36)	PTAU/A β - (n=64)	p
PTAU/A β ₄₂ ratio	0.04 (0.012)	0.01 (0.003)	
A β level (mean, SD)	685.2 (163.7)	1494.2 (401.9)	
Sex (male/female)	26/10	36/28	0.166
BMI (mean, SD)	26.2 (3.8)	25.3 (3.7)	0.338
Age (years, mean, SD)	73.8 (4.9)	72.0 (4.4)	0.039
ApoE ϵ ₄ carrier (n, %)	18 (50%)	14 (22.6%)	0.001
MMSE (mean, SD)	28.5 (1.5)	28.8 (1.4)	0.314
CDR (mean, SD)	0 (0)	0 (0)	
GFAP PG/mL (mean, SD)	211.8 \pm 97.6	138.8 \pm 49.9	<0.001
YKL-40 PG/mL (mean, SD)	N=38, 87038.7 \pm 74252.3	N=145, 60583.7 \pm 54067.1	0.012
MCP-1 PG/mL (mean, SD)	N=34, 92.6 \pm 18.4	N=64, 96.4 \pm 30.7	0.602
Eotaxin-1 PG/mL (mean, SD)	N= 34 193.6 \pm 62.9	N=64 202.5 \pm 86.7	0.630

P values in bold font were considered significant ($p < 0.05$). Independent T-Test, Pearson Chi-Square test and Mann-Whitney tests were applied as appropriate.

CORRELATION BETWEEN BIOMARKERS Figure 1 represents a heatmap with p-values calculated for all inflammatory biomarkers plus A β ₄₂, PTAU/A β ₄₂ ratio and age. Plasma YKL-40, GFAP, A β ₄₂ and PTAU/A β ₄₂ ratio correlated with age. YKL-40 also correlated with GFAP and PTAU/A β ₄₂ ratio. GFAP correlated with PTAU/A β ₄₂ ratio. MCP-1 is positively correlated with Eotaxin-1 and A β ₄₂. A β ₄₂ and PTAU/A β ₄₂ ratio are strongly correlated. N=121 for A β , which are the samples of all original subjects included in the main study except the subjects with a CSF A β ₄₂ concentration of >1700 as no exact concentrations are available.

Figure 1 Heatmap p-values for biomarkers correlations YKL-40, GFAP, eotaxin-1, MCP-1, A β 42, and Ptau/A β 42.




Figure 2 Significant violin plot for GFAP among healthy elderly subjects with a CSF profile consistent with Alzheimer's Disease, n=50 (A β + [CSF A β 42 <1000] versus healthy elderly subjects with normal CSF A β -, n=50 [CSF A β 42 >1000]).





Figure 3 Significant violin plots for GFAP and YKL-40 compared to PTAU/ $A\beta_{42}$ ratio.



DISCUSSION

In the current exploratory study we aimed to investigate plasma biomarkers related to neuroinflammation associated with AD in a cohort of subjects with preclinical AD, and to compare these to healthy elderly, both defined by $A\beta_{1-42}$ CSF status. Of the four inflammatory plasma biomarkers investigated in this study, only GFAP was significantly higher in subjects with preclinical AD compared to healthy elderly. When defining preclinical AD based on the PTAU181/ $A\beta_{1-42}$ ratio, GFAP and YKL-40 were significantly different between groups. This could indicate that GFAP and YKL-40 are more sensitive markers of the incipient inflammatory process that occurs in response to the beta amyloid misfolding and aggregation that is ongoing as indicated by the lowered $A\beta_{1-42}$ protein levels in the CSF.

With increasing prevalence of AD,²⁷ it would be interesting to look at ‘biomarker-positive’ subjects, 50% of whom will develop AD,²⁴ and further investigate the course over time of the inflammatory biomarkers described here. As we found in the current study, evidence of astrogliosis as demonstrated by elevated GFAP was already increased in healthy subjects positive for CSF $A\beta_{1-42}$. If we can further characterize these subjects, we may be able to define a group of healthy subjects more likely to develop AD and treat these subjects in early (neuroinflammatory

or CSF A β_{1-42} lowering) clinical trials. Measurement of GFAP and YKL-40 in plasma is useful in healthy subjects with preclinical AD as it allows to determine the level of neuroinflammation in subjects possibly developing AD and can provide more information on the relationship between neuroinflammation and the development of AD. Disease modifying treatments targeting neuro-inflammation early in the preclinical disease process of AD may delay disease progression and prevent or delay cognitive decline as inflammation can be expected to influence cognitive performance independently from A β pathology.²⁸

Our results showing an increase in GFAP in the preclinical stage are in line with Verberk et al., (2021) who studied a similar population of cognitively healthy elderly and found GFAP to be associated with increased risk of progression to dementia and steeper cognitive decline.¹⁸ A β measured in plasma by Chatterjee et al (2021).¹⁹ in cognitively normal older adults resulted in two groups, A β + and A β - subjects comparable to our studied population. This study also found that GFAP was elevated in subjects with preclinical AD. Our study therefore reproduces these study results, demonstrating that these findings are real and independent of the specific samples used by Chatterjee or by us. Pereira et al., (2021).²⁸ mention that plasma GFAP might be specific to AD as it correlated with A β pathology in their study with comparable cognitive normal subjects, which is supported by the differences between groups found in our study but not the correlation with A β itself. Alternatively, this could be the result of a smaller sample size. Further research is needed to determine if GFAP can be used as a CSF-independent marker for (preclinical) AD.

When YKL-40 is measured in CSF, this could indicate that microglial activation is taking place, even though YKL-40 concentrations are already measurable in subject without lowered A β measured in CSF.²⁹ Several associations have been found between CSF YKL-40 and neurodegenerative biomarkers in CSF namely total tau protein and significant differences have been found between AD patients, healthy elderly, and subjects with preclinical AD.³⁰ Demonstrating differences in plasma levels of YKL-40 between healthy elderly and subjects with preclinical AD could help to identify inflammatory processes in a less invasive manner. In our study, plasma YKL-40 did not correlate with CSF A β_{1-42} and was not different between subjects with preclinical AD and healthy controls. Thus, no conclusion about can be drawn about glial activation by YKL-40 in response to accumulation of A β in this particular sample of healthy subjects, perhaps because it is too early in the disease process to identify differences in YKL-40 concentrations in plasma. When redefining the subjects based on CSF PTAU181/A β_{1-42} ratio scores, plasma YKL-40 concentration was found to differ between groups. This comparison was

performed post hoc, however. As plasma YKL-40 was not previously reported to be different between subjects with preclinical AD and healthy controls, this finding is of interest and a reason to further investigate this and confirm it in a properly powered study aimed at replication. Comparable to GFAP, YKL-40 levels increase with age, in CSF and also in plasma. When measured in plasma, higher plasma YKL-40 concentrations seem to be correlated with male sex, older age, ApoE ϵ 4 status and cerebral accumulation of A β measured with PET.³¹ Our sample did not find YKL-40 to be correlated with age, sex, ApoE ϵ 4 status and A β measured in CSF. GFAP showed to be correlated with sex, age and A β status in our sample. GFAP and YKL-40 can be found in a vast range of peripheral cells expressing it and might therefore be measurable in plasma. Previous studies, however, conclude that measuring GFAP in plasma is related to CNS inflammation and severity of disease.^{32,33} YKL-40 has been found to be increased in subjects with streptococcal pneumonia and could therefore have a peripheral origin and confound to the measurability in plasma which should be taken into account when interpreting YKL-40 results in plasma.³⁴

The subjects investigated in the current study were part of a larger observational study, therefore information on cognitive status measured using a computerized cognitive test battery and several paper and pencil tasks was available. Our two groups, preclinical AD and healthy elderly, were specifically different regarding Abeta-42 measured in CSF. We divided GFAP and YKL-40 scores into 'high' levels and 'low' levels of inflammation by using the median and compared these groups with the total group of subjects. None of the cognitive domains (e.g., memory, attention, overall cognitive performance measured with MMSE and CDR) differed significantly between groups and therefore there was no indication of early cognitive decline in the otherwise healthy subjects with elevated neuroinflammatory markers. This is in contrast to other, longitudinal studies, which have found that plasma (and CSF) GFAP could predict global cognitive decline.¹⁸ even though plasma GFAP was not always measured longitudinally.²⁸

Limitations

The correlation that we found between CSF A β 42 and CSF PTAU/A β 42 ratio is inherently based on the use of CSF A β 42 in the latter ratio. YKL-40 being significantly different in the PTAU/A β 42 ratio condition and not being different based on A β alone could be a result of this.

GFAP correlated significantly with CSF PTAU/A β 42 ratio but not with CSF A β 42, which can possibly be explained by differences in sample size. The calculation of

GFAP in correlation with A β only includes the A β + subjects as these are continuous values (n=50), the A β - subjects all had A β levels of >1700 (no exact value). For calculating the ratio score PTAU/A β ₄₂ the whole data set could be used (n=98) with A β - =1700. When including a larger N, also including the 50 A β - subjects, the correlation between GFAP and CSF A β ₄₂ could have been significant as we have established a difference between groups on GFAP and A β + / A β - subjects. For the calculation of the correlation between A β ₄₂ and age, the original data set of 200 subjects was used, of which 121 subjects had exact A β ₄₂ values. The subjects with A β ₄₂ concentrations of >1700 PG/mL were not included as no exact concentrations were known; it was only indicated that levels were >1700 PG/mL. It is, however, unlikely that the correlation found between A β ₄₂, and age would be non-significant if exact values for all subjects with levels >1700 PG/mL were available.

The subjects included in this study were not referred to a memory clinic but voluntarily participated in this study. No subjects with proof of (subjective) memory complaints participated, demonstrated by a MMSE of >24 during pre-screening, and during the study confirmed by a CDR of 0 and ADL of 0. However, subjects with insecurities about their cognitive performance might be more likely to participate in observational studies.

This study was exploratory and further research is needed to confirm the results. Data in this study was not corrected for multiple comparisons.

Conclusions

Measuring GFAP and YKL-40 in plasma in subjects with preclinical AD could be of added value to further differentiate subjects with lowered CSF A β ₄₂ from otherwise healthy elderly to better define the preclinical AD status. However, this study was cross-sectional and subject discrimination needs further analyses. If further research shows that these inflammatory plasma biomarkers are specific for (preclinical) AD, measuring these can be an important step forward in characterizing otherwise healthy elderly with preclinical AD in a less invasive manner.

REFERENCES

- 1 Blennow, K. and H. Zetterberg, Biomarkers for Alzheimer's disease: current status and prospects for the future. *J Intern Med*, 2018. 284(6): p. 643-663.
- 2 Zetterberg, H. and B.B. Bendlin, Biomarkers for Alzheimer's disease – preparing for a new era of disease-modifying therapies. *Molecular Psychiatry*, 2021. 26(1): p. 296-308.
- 3 Budelier, M.M. and R.J. Bateman, Biomarkers of Alzheimer Disease. *The Journal of Applied Laboratory Medicine*, 2019. 5(1): p. 194-208.
- 4 Bjorkli, C., A. Sandvig, and I. Sandvig, Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients. *Frontiers in Aging Neuroscience*, 2020. 12(272).
- 5 Olsson, B., et al., CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. *Lancet Neurol*, 2016. 15(7): p. 673-684.
- 6 Huang, L.K., S.P. Chao, and C.J. Hu, Clinical trials of new drugs for Alzheimer disease. *J Biomed Sci*, 2020. 27(1): p. 18.
- 7 Dunn, B., P. Stein, and P. Cavazzoni, Approval of Aducanumab for Alzheimer Disease – The FDA's Perspective. *JAMA Internal Medicine*, 2021. 181(10): p. 1276-1278.
- 8 Jansen, W.J., et al., Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis. *JAMA*, 2015. 313(19): p. 1924-1938.
- 9 Saitgareeva, A.R., et al., The role of microglia in the development of neurodegeneration. *Neuro Sci*, 2020.
- 10 Heneka, M.T., et al., Neuroinflammation in Alzheimer's disease. *Lancet Neurol*, 2015. 14(4): p. 388-405.
- 11 Bettcher, B.M., et al., MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes. *Alzheimers Dement (Amst)*, 2016. 3: p. 91-7.
- 12 Haas, D., Chapter 15 - Biomarker for Alzheimer's Disease, in *Precision Medicine*, H.-P. Deigner and M. Kohl, Editors. 2018, Academic Press. p. 333-349.
- 13 Morgan, A.R., et al., Inflammatory biomarkers in Alzheimer's disease plasma. *Alzheimers Dement*, 2019. 15(6): p. 776-787.
- 14 Oeckl, P., et al., Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. *J Alzheimers Dis*, 2019. 67(2): p. 481-488.
- 15 Villar-Pique, A., et al., Plasma γ KL-40 in the spectrum of neurodegenerative dementia. *J Neuroinflammation*, 2019. 16(1): p. 145.
- 16 Muramori, F., K. Kobayashi, and I. Nakamura, A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer's disease, normal controls and non-Alzheimer neuropsychiatric diseases. *Psychiatry Clin Neurosci*, 1998. 52(6): p. 593-9.
- 17 Jesse, S., et al., Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. *J Alzheimers Dis*, 2009. 17(3): p. 541-51.
- 18 Verberk, I.M.W., et al., Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. *The Lancet Healthy Longevity*, 2021. 2(2): p. e87-e95.
- 19 Chatterjee, P., et al., Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. *Transl Psychiatry*, 2021. 11(1): p. 27.
- 20 Mackay, C.R., Chemokines: immunology's high impact factors. *Nat Immunol*, 2001. 2(2): p. 95-101.
- 21 Prins, S., et al., A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation. *Alzheimers Res Ther*, 2021. 13(1): p. 132.
- 22 Lewczuk, P., et al., Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective. *Adv Med Sci*, 2015. 60(1): p. 76-82.
- 23 Willemse, E.A.J., et al., Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. *Alzheimer's & dementia (Amsterdam, Netherlands)*, 2021. 13(1): p. e12182-e12182.
- 24 Blennow, K., et al., Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Abeta(1-42), pTau and tTau CSF immunoassays. *Sci Rep*, 2019. 9(1): p. 19024.
- 25 Campbell, M.R., et al., P-TAU/A β 42 and A β 42/40 ratios in CSF are equally predictive of amyloid PET status. *Alzheimers Dement (Amst)*, 2021. 13(1): p. e12190.

- 26 Teunissen, C.E., et al., A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. *Neurology*, 2009. 73(22): p. 1914-1922.
- 27 WHO. <https://www.who.int/news-room/fact-sheets/detail/dementia>. <https://www.who.int/news-room/fact-sheets/detail/dementia> 2020 21 September 2020 [cited 2021 18Aug2021].
- 28 Pereira, J.B., et al., Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease. *Brain*, 2021.
- 29 Hellwig, K., et al., Neurogranin and γ KL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. *Alzheimer's research & therapy*, 2015. 7: p. 74-74.
- 30 Baldacci, F., et al., Diagnostic function of the neuroinflammatory biomarker γ KL-40 in Alzheimer's disease and other neurodegenerative diseases. *Expert Review of Proteomics*, 2017. 14(4): p. 285-299.
- 31 Vergallo, A., et al., Association of plasma γ KL-40 with brain amyloid- β levels, memory performance, and sex in subjective memory complainers. *Neurobiology of Aging*, 2020. 96: p. 22-32.
- 32 Högel, H., et al., Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. *Mult Scler*, 2020. 26(2): p. 210-219.
- 33 Wu, L., et al., Serum glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 for diagnosis of sepsis-associated encephalopathy and outcome prognostication. *J Crit Care*, 2019. 52: p. 172-179.
- 34 Kronborg, G., et al., Serum level of γ KL-40 is elevated in patients with *Streptococcus pneumoniae* bacteremia and is associated with the outcome of the disease. *Scand J Infect Dis*, 2002. 34(5): p. 323-6.